Novel chimeric antigen receptor T cell-based immunotherapy: a perspective for triple-negative breast cancer

Triple-negative breast cancer (TNBC) is highly aggressive and does not express estrogen receptor (ER), progesterone (PR), or human epidermal growth factor receptor 2 (HER2). It has a poor prognosis, and traditional endocrine and anti-HER2 targeted therapies have low efficacy against it. In contrast,...

Descripción completa

Detalles Bibliográficos
Autores principales: Geng, Peizhen, Chi, Yuhua, Yuan, Yuan, Yang, Maoquan, Zhao, Xiaohua, Liu, Zhengchun, Liu, Guangwei, Liu, Yihui, Zhu, Liang, Wang, Shuai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339351/
https://www.ncbi.nlm.nih.gov/pubmed/37457288
http://dx.doi.org/10.3389/fcell.2023.1158539

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339351/
https://www.ncbi.nlm.nih.gov/pubmed/37457288
http://dx.doi.org/10.3389/fcell.2023.1158539

Ejemplares similares